Press

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

Aug 16 • 7 min read

Quick Take: atai has released their Q2 financial report and business update. This includes details on their IPO, a $20M upfront payment from a collaboration with Otsuka, and $453.6M investment to advance their current programs and explore new ones. atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment…

Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

Aug 13 • 4 min read

Quick Take: Core One Labs’ wholly owned subsidiaries Rejuva Mental Health Clinic and Bluejay Mental Health Group have partnered to assist their patient with submitting an application for an exemption under the Controlled Substances Act. Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in…

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th

Aug 12 • 2 min read

Quick Take: Awakn announces that it is qualified to begin trading on the OTCQB Venture Market under the the ticker “AWKNF” starting today. Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified…

Novamind Divests Non-Core Retreat Investment

Aug 11 • 3 min read

Quick Take: Novamind has announced the completion of its investment in the Synthesis Institute, a psychedelic retreat and practitioner program located in the Netherlands. Novamind Inc. (CSE: NM, OTC: NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company’s investment…

MYND Life Sciences Announces DTC Eligibility

Aug 11 • 2 min read

Quick Take: MYND Life Sciences is now eligible for Depository Trust Company services in relation to the Company’s listing on the OTC. MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is pleased to announce that it is now eligible…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435